david cavalla (20 Ergebnisse)

hardcover. Zustand: Very Good. Zustand des Schutzumschlags: Very Good. Clean and unmarked.

Paperback. Zustand: Very Good. The book has been read, but is in excellent condition. Pages are intact and not marred by notes or highlighting. The spine remains undamaged.

Hardback. Zustand: As New. x 218p hardback, blue and grey cover, like new condition, little to no wear, binding tight, pages clean and bright like new, author's signature on the front endpaper Language: English.

hardcover. Zustand: Very Good. Off-label Prescribing: Justifying Unapproved Medicine This book is in very good condition and will be shipped within 24 hours of ordering. The cover may have some limited signs of wear but the pages are clean, intact and the spine remains undamaged. This book has clearly been well maintained and looked after thus far. Money back guarantee if you are not satisfied. See all our books here, order more than 1 book and get discounted shipping. .

hardcover. Zustand: Very Good. Shipped within 24 hours from our UK warehouse. Clean, undamaged book with no damage to pages and minimal wear to the cover. Spine still tight, in very good condition. Remember if you are not happy, you are covered by our 100% money back guarantee.

Zustand: New. In.

Buch. Zustand: Neu. Neuware - Today's medicines are regulated for their efficacy and safety and, once approved, they can be marketed for certain uses as justified by the data. Regulatory bodies in developed countries are constituted by legal statute and operate as parts of government, ostensibly in the interests of the people as patients.But once approved, medicines can be used for any purpose the prescriber thinks fit and appropriate for the patient. One in five prescriptions is therefore written outside regulatory purview.Off-label Prescribing looks into the corners of our medicated lives, where drug regulation runs up against medical practice, and concerns the use of a drug that has been approved for one use (in medical parlance, 'indication') being used for a different indication; alternatively, being used on a different set of patients from the ones it is approved for, or at a different dose. Usually the patient is unaware of what is going on, having not been informed by their doctor of this aspect of his or her prescribing choice.The book examines how and why this occurs, what the various medical professions have to say about it, and how pharmaceutical companies benefit by moving into this poorly regulated area. Off-label Prescribing pulls these complex issues together in one volume, to highlight current practice, its advantages and weaknesses and how the author suggests practice should evolve in the future. It will therefore be of interest to all those who prescribe (and receive) medicines, combined with a greater objective to provide more transparency and discussion for professionals.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

Zustand: New. In.

Zustand: New. In.

Gebunden. Zustand: New. Drug Repurposing provides an ideal introduction to the field of drug repositioning and repurposing with contributions from world-renowned experts culminating in an excellent resource for any drug discovery or medicinal chemist.Klappentextrnr.

Hardcover. Zustand: Brand New. gld edition. 400 pages. 9.21x6.14x1.00 inches. In Stock.

Zustand: New. pp. 228.

Buch. Zustand: Neu. Neuware - Drug repurposing, or repositioning, is the development of existing drugs for new uses: given that 9 in 10 drugs that enter drug development are never marketed and therefore represent wasted effort, it is an attractive as well as inherently more efficient process. Three repurposed drugs can be brought to market for the same cost as one new chemical entity; and they can also be identified more quickly, an important benefit for patients whose diseases are progressing faster than therapeutic innovation. But repurposing also requires a fresh look at configuring pharmaceutical R&D, considering clinical, regulatory and patent issues much earlier than would otherwise be the case. In addition to new ways of thinking, the discovery of repurposing opportunities can take advantage of artificial intelligence techniques to match the perfect new use for an existing drug. This book provides an ideal introduction to the field of drug repurposing with contributions from world-renowned experts culminating in an excellent resource for any drug discovery or medicinal chemist.

Hardcover. Zustand: Brand New. 1st edition. 218 pages. 9.00x6.25x0.75 inches. In Stock.

Zustand: New. The emphasis on cost-effectiveness within the pharmaceutical industry has caused it to outsource some development work. This text addresses the advantages and disadvantages of collaborations between industrial research and development divisions and contract research organizations and universities. Num Pages: 228 pages, Ill. BIC Classification: KNDP; MBGR; TDCW. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 242 x 165 x 18. Weight in Grams: 488. . 1997. 1st Edition. Hardcover. . . . . Books ship from the US and Ireland.

Buch. Zustand: Neu. Neuware - The twentieth century has been a great success for modern medicine,and has resulted in the generation of a plethora of drugs to treatmost common illnesses. However, in the light of increasingregulatory demands, spiralling costs and diminishing commercialreturns, the question of how, when, where and whether to conductpharmaceutical R&D has profound implications, and not just forthose within the pharmaceutical industry. In response to these andother dilemmas, the authors define the processes involved in drugresearch, and examine the advantages and disadvantages ofcollaborative methods of drug research, and examine the roles thatacademia, CROs, small 'biotechnology' companies and 'researchboutiques,' and possibly even the 'virtual research company' mightplay as contractors and collaborators.

58 pp.; 27 x 26.9 cm.; staple bound; black-and-white & color; edition size unknown; unsigned and unnumbered; offset-printed; Issue edited by Philip Leider. Essays "Culture & Subsidy: A Report on the U.C.L.A. Arts Convention," by Keith Boyle; "Emil Nolde," by Alfred Werner; "Three San Francisco Artists," by James Monte; "Four Drawings," by John Hultberg; "Are We Getting Anywhere?" by Henry Miller; "Marcel Cavalla," by Rosalind G. Wholden "Review and Response," by Don Factor and Howard Warshaw. Reviews by Fidel A. Danieli, Irma E. Desenberg, Don Factor, Joan Hugo, Jorgen L. Hansen, George R. James, Doug McClellan, Constance Perkins, Shirley Y. Pettibone, Donald Totten, Harriette von Breton, Rosalind G. Wholden, H.J. Weeks, David Gebhard, Delores Yonker. Cover: Emil Nolde, "Dancer," 1913. Good. Rubbing of covers and bumping of corners. Wrinkling on bottom left corner of verso and 4 cm. dog ear on top left corner of verso. Contents clean and unmarked.